An outstanding achievement has been made both financially and professionally by the cooperation of SONEAS Research Ltd. and AVIDIN Ltd. in medical development.
AVIDIN has been researched the cure for Alzheimer disease since 2009. During chemical and biological developments at a molecular level a new drug candidate had been discovered (Q134R-K), which was patented by the company and its partners all over the world by the name of ‘Kinolol’. As the partner of AVIDIN, SONEAS started the Phase I experiments in 2012, which were successfully closed on 15 December 2017.
The Hungarian Government supported the project through the New Széchenyi Plan, with the coordination of the National Development Agency, and with the funding of the National Research, Development and Innovation Fund.
Alzheimer is considered as being a serious, incurable disease, but the Q134R-K candidate means not only a symptomatic treatment, but due to its original mechanism it might stop the progression of it and can significantly improve the mental health.
SONEAS handed in its 700-page long final report on the completion of Phase I studies to OGYÉI on 15 December 2017. The Clinical Study Report means the completion of Phase I studies.
The Phase I clinical studies started on 17 October 2016 and finished on 5 January 2017. It was proven that the Q134R-K drug candidate is properly absorbing and is safe, there were no serious side effects occurring during the tests.
In the framework of the successful tender, with the involvement of large companies from all over the world, the mechanism of the drug candidate was successfully revealed, which shed light to the effects that can stop the further development of the disease. The revolutionary mechanism of the Q-134R-K molecule had brought the attention of the scientific world. The processes which are intended to protect the neurons is being tested in one of the seven centres in the USA designed to research Alzheimer’s, at Kentucky University, where a well-known researcher of the area undertakes the activity with financial support from the Alzheimer’s Drug Discovery Foundation (ADDF). He presented the first results on the 13th International Conference on Alzheimer’s and Parkinson’s Disease (AD/AP) in 2017. The Alzheimer is primarily the disease of the elder generations, a progressive, degenerative, neurological diseases, the most common form of dementia.
It is characterized by the gradual loss of memory and cognitive functions, which can evolve to a level where it makes everyday activities a challenge. In the final phase the patient becomes incapacitated and is basically tied to bed. Currently about 44 million people suffer from Alzheimer’s Disease in the world, and according to the statistics this number doubles every 20 years. Alzheimer is among the most serious and costly diseases. In 2016 in the United States alone the treatment of the 5.3 million patients costs 236 billion dollars. There is no such medication on the market which would be able to prevent or stop the disease or postponing its harsh symptoms.